KALA BIO to Present at Jefferies Global Healthcare Conference
May 29, 2024 08:00 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative...
KALA BIO Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14, 2024 16:05 ET
|
KALA BIO, Inc.
-- Patient enrollment ongoing in Phase 2b CHASE trial of KPI-012 for PCED; targeting topline data by year-end 2024 -- -- Evaluating opportunities to expand KPI-012 development into other corneal...
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 29, 2024 08:00 ET
|
KALA BIO, Inc.
-- Advancing ongoing Phase 2b CHASE trial of KPI-012 for PCED; topline data targeted by year-end 2024 ---- Exploring opportunities to expand KPI-012 into additional corneal indications ---- Cash...
KALA BIO to Present at TD Cowen 44th Annual Healthcare Conference
February 26, 2024 08:00 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
KALA BIO to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 08:00 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 19, 2024 16:01 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award...
KALA BIO Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 13, 2023 08:00 ET
|
KALA BIO, Inc.
-- Enrollment ongoing in CHASE Phase 2b clinical trial of KPI-012 for PCED; topline data expected in 2H 2024 ---- As of September 30, 2023, $56.1 million in cash and cash equivalents; together with...
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 20, 2023 16:01 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award...
KALA BIO to Present at H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023 08:00 ET
|
KALA BIO, Inc.
ARLINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of...
KALA BIO Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 04, 2023 08:00 ET
|
KALA BIO, Inc.
-- Actively enrolling patients in CHASE Phase 2b clinical trial of KPI-012 for the treatment of PCED; topline data targeted for 2Q 2024 -- -- Combangio, Inc., a wholly owned subsidiary of KALA,...